The episodic GnRH release from the hypothalamic GnRH pulse generator, controlled by excitatory and inhibitory neurotransmitters as well as neuropeptides and glial factors, induces the pulsatile ...
MIAMI, June 10, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, ...
Use of a gonadotropin-releasing hormone antagonist is associated with lower risks for death than GnRH agonists, a systematic review and meta-analysis found. Use of degarelix, a gonadotropin-releasing ...
The REVELUTION (Relugolix versus Leuprolide Cardiac) trial compared coronary plaque after 2 types of androgen deprivation therapy (ADT) for prostate cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results